SCHEMBL6310328

SCHEMBL6310328

CCc1c(C)c(C#N)c2nc3ccccn3c2c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 1/20 0.44
MDM2 Q00987 1/20 0.44
KDM4E B2RXH2 9/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
HK1 P19367 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
GAA P10253 3/20 0.39
TDP1 Q9NUW8 1/20 0.39
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
SLC2A1 P11166 1/20 0.37
ALDH1A1 P00352 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312086 0.90 MAPT (0.47) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6311562 0.88 HPGD (0.43) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6310742 0.88 HPGD (0.43) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6311004 0.87 ENPP2 (0.43) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6312786 0.86 KDM4E (0.44) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6311550 0.85 KDM4E (0.48) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6318124 0.84 ALDH1A1 (0.43) NPSR1MAPTRAB9ASMN1; SMN2LMNA
SCHEMBL6312701 0.84 ENPP2 (0.43) NPSR1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL6309849 0.83 KDM4E (0.41) NPSR1MAPTRAB9ANPC1KDM4E
SCHEMBL6317979 0.82 ADORA3 (0.43) NPSR1MAPTRAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 NPSR1 1531/4885MAPT 1694/4885RAB9A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.